Wuxi Biologics (Cayman) (WXIBF) Stock Forecast & Price Target

Compare

129 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WXIBF Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Wuxi

Biologics (Cayman)

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WXIBF Stock 12 Month Forecast

Average Price Target

$4.07

▲(20.41%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Wuxi Biologics (Cayman) in the last 3 months. The average price target is $4.07 with a high forecast of $5.73 and a low forecast of $2.98. The average price target represents a 20.41% change from the last price of $3.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.73399,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.9816748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3,3.210306923076923,3.420613846153846,3.6309207692307695,3.8412276923076925,4.0515346153846155,4.261841538461539,4.4721484615384615,4.682455384615385,4.892762307692308,5.103069230769231,5.313376153846154,5.523683076923078,{"y":5.73399,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3,3.082307692307692,3.164615384615385,3.246923076923077,3.329230769230769,3.411538461538462,3.493846153846154,3.5761538461538462,3.6584615384615384,3.740769230769231,3.8230769230769233,3.905384615384616,3.987692307692308,{"y":4.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3,2.998590369230769,2.9971807384615383,2.9957711076923075,2.994361476923077,2.9929518461538462,2.9915422153846154,2.9901325846153846,2.9887229538461537,2.987313323076923,2.9859036923076925,2.9844940615384616,2.983084430769231,{"y":2.9816748,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$5.73

Average Price Target$4.07

Lowest Price Target$2.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yang HuangJ.P. Morgan

J.P. Morgan

$4.08→$3.57

Buy

5.56%

Upside

Reiterated

05/06/25

Wuxi Biologics (2269:HK) (WXXWY) PT Lowered to HK$28 at JPMorganJPMorgan analyst Yang Huang lowered the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$28.00 (from HK$32.00) while maintaining a Overweight rating.

Cui CuiJefferies

Jefferies

$5.73

Buy

69.64%

Upside

Reiterated

03/31/25

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Jefferies

John YungCiti

Citi

$3.82→$4.46

Buy

31.95%

Upside

Reiterated

03/31/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$35 at CitiCiti analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$35.00 (from HK$30.00) while maintaining a Buy rating.

Jill WuCMB International Securities

CMB International Securities

$3.09→$3.94

Buy

16.64%

Upside

Reiterated

03/27/25

WuXi Biologics: Strong Growth and Strategic Expansion Drive Buy Rating and Target Price Increase

Michael Luo CFACLSA

CLSA

$3.31→$3.67

Buy

8.57%

Upside

Reiterated

03/27/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$28.80 at CLSACLSA analyst Michael Luo raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$28.80 (from HK$26.00) while maintaining a Outperform (2) rating.

Ziyi ChenGoldman Sachs

Goldman Sachs

$2.65→$2.98

Hold

-11.78%

Downside

Reiterated

03/27/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$23.40 at Goldman SachsGoldman Sachs analyst Ziyi Chen raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$23.40 (from HK$20.80) while maintaining a Neutral rating.

Unknown AnalystUOB Kay Hian

Not Ranked

UOB Kay Hian

$4.46

Buy

31.95%

Upside

Reiterated

03/27/25

Jialin ZhangNomura

Nomura

$3.9→$4.38

Buy

29.53%

Upside

Reiterated

03/26/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$34.36 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$34.36 (from HK$30.59) while maintaining a Buy rating.

Tony RenMacquarie

Macquarie

$3.44

Hold

1.79%

Upside

Reiterated

03/26/25

Macquarie Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)Macquarie analyst Tony Ren reiterated a Neutral rating and HK$27.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Nico ChenDBS

DBS

$3.06

Hold

-9.52%

Downside

Reiterated

02/24/25

Hold Rating for WuXi Biologics Amid Biosecure Act Risks and Regulatory Challenges

Sean Wu CFAMorgan Stanley

Morgan Stanley

$4.08

Buy

20.64%

Upside

Reiterated

08/30/24

Morgan Stanley Reiterates Overweight Rating on Wuxi Biologics (2269:HK) (WXXWY)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$32.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Chen ChenUBS

UBS

$2.12

Hold

-37.42%

Downside

Reiterated

06/12/24

UBS Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)UBS analyst Chen Chen reiterated a Neutral rating and HK$16.60 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yang HuangJ.P. Morgan

J.P. Morgan

$4.08→$3.57

Buy

5.56%

Upside

Reiterated

05/06/25

Cui CuiJefferies

Jefferies

$5.73

Buy

69.64%

Upside

Reiterated

03/31/25

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Jefferies

John YungCiti

Citi

$3.82→$4.46

Buy

31.95%

Upside

Reiterated

03/31/25

Jill WuCMB International Securities

CMB International Securities

$3.09→$3.94

Buy

16.64%

Upside

Reiterated

03/27/25

WuXi Biologics: Strong Growth and Strategic Expansion Drive Buy Rating and Target Price Increase

Michael Luo CFACLSA

CLSA

$3.31→$3.67

Buy

8.57%

Upside

Reiterated

03/27/25

Ziyi ChenGoldman Sachs

Goldman Sachs

$2.65→$2.98

Hold

-11.78%

Downside

Reiterated

03/27/25

Unknown AnalystUOB Kay Hian

Not Ranked

UOB Kay Hian

$4.46

Buy

31.95%

Upside

Reiterated

03/27/25

Jialin ZhangNomura

Nomura

$3.9→$4.38

Buy

29.53%

Upside

Reiterated

03/26/25

Tony RenMacquarie

Macquarie

$3.44

Hold

1.79%

Upside

Reiterated

03/26/25

Macquarie Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)Macquarie analyst Tony Ren reiterated a Neutral rating and HK$27.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Nico ChenDBS

DBS

$3.06

Hold

-9.52%

Downside

Reiterated

02/24/25

Hold Rating for WuXi Biologics Amid Biosecure Act Risks and Regulatory Challenges

Sean Wu CFAMorgan Stanley

Morgan Stanley

$4.08

Buy

20.64%

Upside

Reiterated

08/30/24

Chen ChenUBS

UBS

$2.12

Hold

-37.42%

Downside

Reiterated

06/12/24

UBS Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)UBS analyst Chen Chen reiterated a Neutral rating and HK$16.60 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wuxi Biologics (Cayman)

1 Month

xxx

Success Rate

3/6 ratings generated profit

Average Return

+2.03%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.03% per trade.

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+8.62%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.62% per trade.

1 Year

Jialin ZhangNomura

Success Rate

4/6 ratings generated profit

Average Return

+37.18%

reiterated a buy rating 3 months ago

Copying Jialin Zhang's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +37.18% per trade.

2 Years

xxx

Success Rate

4/6 ratings generated profit

Average Return

+45.38%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +45.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WXIBF Analyst Recommendation Trends

Rating

Dec 24

Jan 25

Feb 25

Mar 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WXIBF has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. WXIBF average Analyst price target in the past 3 months is 4.07.

Each month's total comprises the sum of three months' worth of ratings.

WXIBF Financial Forecast

WXIBF Earnings Forecast

Next quarter’s earnings estimate for WXIBF is $0.06 with a range of $0.06 to $0.06. The previous quarter’s EPS was $0.03. WXIBF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year WXIBF has Preformed in-line its overall industry.

WXIBF Sales Forecast

Next quarter’s sales forecast for WXIBF is $1.34B with a range of $1.34B to $1.34B. The previous quarter’s sales results were $1.41B. WXIBF beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 70.18% of the time in the same period. In the last calendar year WXIBF has Outperformed its overall industry.

WXIBF Stock Forecast FAQ

What is WXIBF’s average 12-month price target, according to analysts?

Based on analyst ratings, Wuxi Biologics (Cayman) Inc.’s 12-month average price target is 4.07.

What is WXIBF’s upside potential, based on the analysts’ average price target?

Wuxi Biologics (Cayman) Inc. has 20.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WXIBF a Buy, Sell or Hold?

Wuxi Biologics (Cayman) Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is Wuxi Biologics (Cayman) Inc.’s price target?

The average price target for Wuxi Biologics (Cayman) Inc. is 4.07. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.73 ,the lowest forecast is $2.98. The average price target represents 20.41% Increase from the current price of $3.38.

What do analysts say about Wuxi Biologics (Cayman) Inc.?

Wuxi Biologics (Cayman) Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of WXIBF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Wuxi Biologics (Cayman) (WXIBF) Stock Forecast & Price Target

WXIBF Analyst Ratings

WXIBF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wuxi Biologics (Cayman)

WXIBF Analyst Recommendation Trends

WXIBF Financial Forecast

WXIBF Earnings Forecast

WXIBF Sales Forecast

WXIBF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts